Benefits of TOBI

The Cystic Fibrosis Foundation (CFF) states that inhaled tobramycin is one of the most widely used treatments for people with cystic fibrosis (CF).

TOBI has been available to treat Pseudomonas aeruginosa in the lungs of people with CF for over a decade. It is approved for people aged 6 and over with a lung function within a certain range.

In clinical studies, taking TOBI twice daily to treat Pseudomonas aeruginosa resulted in:

IMPROVED LUNG FUNCTION (primary end point)

In clinical studies, people with CF who treated Pseudomonas aeruginosa with TOBI saw their FEV1 improve by 10% on average from baseline compared with a 2% decline in FEV1 in patients receiving placebo at 20 weeks. People who did not take TOBI had worse lung function at the end of the studies

 

FEWER DAYS IN THE HOSPITAL

In clinical studies, people with CF treated with TOBI had 37% fewer days in the hospital versus placebo (5.1 days vs 8.1 days, respectively)

 

LESS NEED FOR IV ANTIPSEUDOMONAL ANTIBIOTICS

Clinical studies show that when people with CF treat Pseudomonas aeruginosa with TOBI, there are 32% fewer days receiving IV antipseudomonal antibiotics versus placebo (9.6 and 14.1 days, respectively) than people who did not take TOBI

 

TOBItime.com

What do you think is the single most important benefit of taking TOBI?

Which activity do you do most often when taking your TOBI treatment?

Eligible Patients Pay only a $10 co-pay for TOBI

Eligible Patients Pay only a $10 Co-Pay for TOBI

LEARN more
 
Important Safety Information full Prescribing Information Patient Product Information www.fda.gov/medwatch